This is a study of the drug perifosine given in combination with docetaxel. Perifosine is an
oral anti-cancer agent that has been used in more than 140 people. Docetaxel is a standard
chemotherapy agent used in many types of cancer. This study is designed to determine the
highest dose of perifosine that can be administered to people every day while they are
receiving docetaxel with or without a steroid called prednisone, without severe or prolonged
nausea, vomiting and diarrhea. This study starts with patients taking 50 mg/day and goes up
to 150 mg/day.